CompletedNCT01439126

Efficacy & Safety of KAPVAY™ Extended-Release in Children & Adolescents With Attention Deficit Hyperactivity Disorder

This study evaluated the safety and effectiveness of clonidine hydrochloride for people with ADHD.

Medication studyAges 6–17

The study in practice

Understand this study

This study evaluated the safety and effectiveness of clonidine hydrochloride for people with ADHD.

This study was for people with ADHD. Listed age limits: 6 years to 17 years. Other eligibility criteria applied.

Study clarity

Study start dateAugust 2011

Recruitment status: Completed
Enrollment listed in the registry: 135
Sponsor: Concordia Pharmaceuticals Inc., Barbados
Sponsor type: Other organization
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 4
Locations: Not clearly listed
Age range: From 6 Years to 17 Years
Official registry ID: NCT01439126
Official title: Show the full official title
A 40-Week, Phase 4, Double-Blind, Placebo-Controlled, Multicenter, Randomized-Withdrawal Study to Evaluate the Long-Term Efficacy and Safety of KAPVAY™ (Clonidine Hydrochloride) Extended-Release in Children and Adolescents With ADHD

Completed

Locations not listed

FAQ

What did researchers investigate?

This study evaluated the safety and effectiveness of clonidine hydrochloride for people with ADHD.

Who is behind this study?

The study sponsor is Concordia Pharmaceuticals Inc., Barbados.

Did this study involve medication?

Yes. The study involved medication, including clonidine hydrochloride and Placebo.

Who was this study for?

This study was for people with ADHD. Listed age limits: 6 years to 17 years. Other eligibility criteria applied.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.